3 Vaccine Maker, Surfactant and Pizza Chain Stocks With a Strong Future Roadmap: GlaxoSmithKline Pharmaceuticals, Galaxy Surfactants and Jubilant FoodWorks
- October 19, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
GSK Pharma Rs 2,566.10, P/E 40.20. Galaxy Surfactants Rs 2,502.00, P/E 24.09. Jubilant FoodWorks Rs 417.95, P/E 62.77. Closing prices of 14 Oct 2026.
Quick Answer
Vaccine maker, surfactant and pizza chain stocks with the clearest long-term roadmaps today include GSK Pharma in branded medicines and vaccines sold through a large doctor network, Galaxy Surfactants in surfactants and specialty ingredients for personal care and home care brands and Jubilant FoodWorks in Domino’s Pizza stores across India and neighbouring markets, along with newer food brands. FY26 revenue growth was 1.8% at GSK Pharma, 24.2% at Galaxy Surfactants and 17.2% at Jubilant FoodWorks. P/E stands at 40.20 for GSK Pharma (industry 37.59), 24.09 for Galaxy Surfactants (industry 36.60) and 62.77 for Jubilant FoodWorks (industry 61.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Vaccine maker, surfactant and pizza chain stocks give investors exposure to medicines, personal care ingredients and eating out. Volumes, pricing and margins decide how much of that demand turns into profit.
This list covers three vaccine maker, surfactant and pizza chain stocks: GlaxoSmithKline Pharmaceuticals for branded medicines and vaccines sold through a large doctor network, Galaxy Surfactants for surfactants and specialty ingredients for personal care and home care brands and Jubilant FoodWorks for Domino’s Pizza stores across India and neighbouring markets, along with newer food brands. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Vaccine Maker, Surfactant and Pizza Chain Stocks?
Vaccine maker, surfactant and pizza chain stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Vaccine Maker, Surfactant and Pizza Chain Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three vaccine maker, surfactant and pizza chain stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals | 2,566.10 | 42,939 | 40.20 | 37.59 | 45.69% | 0.01 |
| Galaxy Surfactants | 2,502.00 | 8,524 | 24.09 | 36.60 | 9.74% | 0.09 |
| Jubilant FoodWorks | 417.95 | 28,248 | 62.77 | 61.79 | 18.69% | 2.14 |
Among healthcare, chemicals and consumer stocks, GSK Pharma trades at a premium to the industry P/E, while Galaxy Surfactants trades at a discount.
Why Do Vaccine Maker, Surfactant and Pizza Chain Stocks Have a Strong Roadmap in India?
Vaccine maker, surfactant and pizza chain stocks have a strong roadmap in India because vaccination demand, personal care brand volumes and more eating out keep adding volumes for these firms. Three drivers stand out.
- Vaccination demand: Doctors prescribe more vaccines and branded medicines.
- Personal care: Brands buy surfactants for soaps and shampoos.
- Eating out: Families order from pizza and food chains.
GlaxoSmithKline Pharmaceuticals: Branded Medicines and Vaccines Anchor the Roadmap
GSK Pharma’s roadmap rests on branded medicines and vaccines sold through a large doctor network, with established brands supporting steady sales.
Revenue grew from Rs 3,353.80 crore in FY22 to Rs 3,967.03 crore in FY26, an 18.3% rise, and FY26 revenue was 1.8% higher than FY25. FY26 net profit rose 11.7% to Rs 1,035.98 crore. Over four years, net profit rose from Rs 380.77 crore in FY22 to Rs 1,035.98 crore. In Q1 FY27, revenue grew 15.7% to Rs 982.20 crore, and net profit rose 15.7% to Rs 237.18 crore. Operating margin was 38.60% in FY26.
Debt to equity is 0.01 and return on equity is 45.69%. FY26 operating cash flow was Rs 903.30 crore against capital expenditure of Rs 55.28 crore. GSK Pharma paid a dividend of Rs 57 per share for FY26, a yield of 2.25%. At a P/E of 40.20 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 40.20 is a modest premium to the industry P/E of 37.59, so the next quarters’ growth is the figure to follow.
Galaxy Surfactants: Personal Care Ingredients Anchor the Roadmap
Galaxy Surfactants’ roadmap rests on surfactants and specialty ingredients for personal care and home care brands, with global consumer companies as customers supporting volumes.
Revenue grew from Rs 3,698.22 crore in FY22 to Rs 5,279.92 crore in FY26, a 42.8% rise, and FY26 revenue was 24.2% higher than FY25. FY26 net profit was Rs 267.38 crore. In Q1 FY27, revenue grew 38.5% to Rs 1,785.18 crore. Operating margin was 9.25% in FY26 and 14.17% in Q1 FY27 against 10.57% a year earlier.
Debt to equity is 0.09 and return on equity is 9.74%. FY26 operating cash flow was Rs 332.66 crore against capital expenditure of Rs 136.95 crore. Galaxy Surfactants paid a dividend of Rs 22 per share for FY26, a yield of 0.91%. At a P/E of 24.09 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 14.17% against 9.25% for FY26, so margin stability is the figure to follow as volumes grow.
Jubilant FoodWorks: Domino’s Store Network Anchors the Roadmap
Jubilant FoodWorks’ roadmap rests on Domino’s Pizza stores across India and neighbouring markets, along with newer food brands, with store additions and delivery reach supporting sales.
Revenue grew from Rs 4,437.48 crore in FY22 to Rs 9,586.64 crore in FY26, a 116.0% rise, and FY26 revenue was 17.2% higher than FY25. FY26 net profit rose 54.4% to Rs 386.03 crore. In Q1 FY27, revenue grew 13.6% to Rs 2,588.34 crore, and net profit rose 6.0% to Rs 100.03 crore. Operating margin was 20.96% in FY26 and 20.37% in Q1 FY27 against 20.21% a year earlier.
Debt to equity is 2.14 and return on equity is 18.69%. FY26 operating cash flow was Rs 1,893.55 crore against capital expenditure of Rs 1,009.93 crore. Jubilant FoodWorks paid a dividend of Rs 1.2 per share for FY26, a yield of 0.28%. At a P/E of 62.77 against an industry P/E of 61.79, the stock trades in line with its industry multiple.
What to watch: Debt to equity of 2.14 is on the higher side, and net profit margin is only 4.0%, so small cost changes move earnings.
Best Vaccine Maker, Surfactant and Pizza Chain Stocks in India: GSK Pharma vs Galaxy Surfactants vs Jubilant FoodWorks on Key Financials
Among the best vaccine maker, surfactant and pizza chain stocks in India, GSK Pharma leads on FY26 operating margin and return on equity; Galaxy Surfactants leads on FY26 revenue growth and Q1 FY27 revenue growth; Jubilant FoodWorks ranks second on FY26 revenue growth and FY26 operating margin. The table puts the numbers side by side.
| Metric | GSK Pharma | Galaxy Surfactants | Jubilant FoodWorks |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 3,967.03 | 5,279.92 | 9,586.64 |
| FY26 revenue growth | 1.8% | 24.2% | 17.2% |
| FY26 net profit (Rs Cr) | 1,035.98 | 267.38 | 386.03 |
| FY26 operating profit margin | 38.60% | 9.25% | 20.96% |
| Q1 FY27 revenue growth (YoY) | 15.7% | 38.5% | 13.6% |
| Return on equity | 45.69% | 9.74% | 18.69% |
| P/E ratio | 40.20 | 24.09 | 62.77 |
| Debt to equity | 0.01 | 0.09 | 2.14 |
| Dividend yield | 2.25% | 0.91% | 0.28% |
| FY26 operating cash flow (Rs Cr) | 903.30 | 332.66 | 1,893.55 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Vaccine Maker, Surfactant and Pizza Chain Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen vaccine maker, surfactant and pizza chain stocks and shortlist vaccine maker, surfactant and pizza chain stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these vaccine maker, surfactant and pizza chain stocks
Risks to Consider Before Investing in Vaccine Maker, Surfactant and Pizza Chain Stocks
- Debt and cash flow: Jubilant FoodWorks has debt to equity of 2.14.
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track GSK Pharma, Galaxy Surfactants and Jubilant FoodWorks live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover vaccines, surfactants and restaurants. GSK Pharma leads on FY26 operating margin and return on equity; Galaxy Surfactants leads on FY26 revenue growth and Q1 FY27 revenue growth; Jubilant FoodWorks ranks second on FY26 revenue growth and FY26 operating margin.
Across vaccine maker, surfactant and pizza chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the vaccine maker, surfactant and pizza chain stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Vaccine Maker, Surfactant and Pizza Chain Stocks
Which are the best vaccine maker, surfactant and pizza chain stocks in India with a strong roadmap?
Ans. GlaxoSmithKline Pharmaceuticals, Galaxy Surfactants and Jubilant FoodWorks stand out for their roadmaps in vaccines, surfactants and restaurants. FY26 revenue growth was 1.8% at GSK Pharma, 24.2% at Galaxy Surfactants and 17.2% at Jubilant FoodWorks, and return on equity ranges from 9.74% to 45.69%.
Is GlaxoSmithKline Pharmaceuticals a good stock to buy now?
Ans. GlaxoSmithKline Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 45.69% and a P/E of 40.20 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of GSK Pharma, Galaxy Surfactants and Jubilant FoodWorks?
Ans. The P/E ratio is 40.20 for GSK Pharma (industry 37.59), 24.09 for Galaxy Surfactants (industry 36.60) and 62.77 for Jubilant FoodWorks (industry 61.79). Only GSK Pharma and Jubilant FoodWorks trade at or above the industry multiple.
Which of these vaccine maker, surfactant and pizza chain stocks has the highest return on equity?
Ans. GlaxoSmithKline Pharmaceuticals has the highest return on equity at 45.69%, followed by Jubilant FoodWorks at 18.69% and Galaxy Surfactants at 9.74%.
What are the risks of investing in vaccine maker, surfactant and pizza chain stocks?
Ans. The main risks are debt and cash flow, consumer demand, input costs and quarterly trends. Jubilant FoodWorks has debt to equity of 2.14.
How did GSK Pharma, Galaxy Surfactants and Jubilant FoodWorks perform in Q1 FY27?
Ans. GlaxoSmithKline Pharmaceuticals reported revenue of Rs 982.20 crore, up 15.7% year on year, and net profit rose 15.7% to Rs 237.18 crore. Galaxy Surfactants reported revenue of Rs 1,785.18 crore, up 38.5% year on year. Jubilant FoodWorks reported revenue of Rs 2,588.34 crore, up 13.6% year on year, and net profit rose 6.0% to Rs 100.03 crore.
Do vaccine maker, surfactant and pizza chain stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 2.25% for GSK Pharma, 0.91% for Galaxy Surfactants and 0.28% for Jubilant FoodWorks, based on dividends declared for FY26.
How can I invest in vaccine maker, surfactant and pizza chain stocks in India?
Ans. You can buy vaccine maker, surfactant and pizza chain stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
